BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749-756. [PMID: 26719299 DOI: 10.1136/gutjnl-2015-310861] [Cited by in Crossref: 368] [Cited by in F6Publishing: 329] [Article Influence: 52.6] [Reference Citation Analysis]
Number Citing Articles
1 Xiong J, Wang Y, Xu W, Liu Z, Wang H, Zhang Z, Han Y, Yin C, Cao S, Yang Z, Su T, Wei J, Chen G, Jin L. Proton pump inhibitors and odds of cholangiocarcinoma: A retrospective case‐control study. Liver Int 2020;40:2848-57. [DOI: 10.1111/liv.14663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 García Rodríguez LA, Lanas A, Soriano-Gabarró M, Vora P, Cea Soriano L. Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. J Clin Med 2020;9:E928. [PMID: 32231106 DOI: 10.3390/jcm9040928] [Reference Citation Analysis]
3 Anhê FF, Varin TV, Schertzer JD, Marette A. The Gut Microbiota as a Mediator of Metabolic Benefits after Bariatric Surgery. Canadian Journal of Diabetes 2017;41:439-47. [DOI: 10.1016/j.jcjd.2017.02.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
4 Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12:24-33. [PMID: 28550391 DOI: 10.1007/s12072-017-9798-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
5 Millien V, Rosen D, Hou J, Shah R. Proinflammatory Sulfur-Reducing Bacteria Are More Abundant in Colonic Biopsies of Patients with Microscopic Colitis Compared to Healthy Controls. Dig Dis Sci 2019;64:432-8. [DOI: 10.1007/s10620-018-5313-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
6 Tsuboi M, Niikura R, Hayakawa Y, Hirata Y, Ushiku T, Koike K. Distinct Features of Autoimmune Gastritis in Patients with Open-Type Chronic Gastritis in Japan. Biomedicines 2020;8:E419. [PMID: 33066474 DOI: 10.3390/biomedicines8100419] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Parsons BN, Ijaz UZ, D'Amore R, Burkitt MD, Eccles R, Lenzi L, Duckworth CA, Moore AR, Tiszlavicz L, Varro A, Hall N, Pritchard DM. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017;13:e1006653. [PMID: 29095917 DOI: 10.1371/journal.ppat.1006653] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 16.2] [Reference Citation Analysis]
8 Knight R, Vrbanac A, Taylor BC, Aksenov A, Callewaert C, Debelius J, Gonzalez A, Kosciolek T, Mccall L, Mcdonald D, Melnik AV, Morton JT, Navas J, Quinn RA, Sanders JG, Swafford AD, Thompson LR, Tripathi A, Xu ZZ, Zaneveld JR, Zhu Q, Caporaso JG, Dorrestein PC. Best practices for analysing microbiomes. Nat Rev Microbiol 2018;16:410-22. [DOI: 10.1038/s41579-018-0029-9] [Cited by in Crossref: 529] [Cited by in F6Publishing: 443] [Article Influence: 132.3] [Reference Citation Analysis]
9 Cannon MD, Martin P, Carrion AF. Bacterial Infection in Patients with Cirrhosis: Don't Get Bugged to Death. Dig Dis Sci 2020;65:31-7. [PMID: 31768880 DOI: 10.1007/s10620-019-05943-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Coman V, Vodnar DC. Gut microbiota and old age: Modulating factors and interventions for healthy longevity. Exp Gerontol 2020;141:111095. [PMID: 32979504 DOI: 10.1016/j.exger.2020.111095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
11 Waszczuk E, Waszczuk K. Gluten, Dysbiosis, and Genetics in Celiac Disease: All Are Important. Dig Dis Sci 2016;61:2761-2. [PMID: 27480087 DOI: 10.1007/s10620-016-4264-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Spanogiannopoulos P, Turnbaugh PJ. Broad collateral damage of drugs against the gut microbiome. Nat Rev Gastroenterol Hepatol 2018;15:457-8. [PMID: 29752457 DOI: 10.1038/s41575-018-0028-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
13 Stephens C, Lucena MI, Andrade RJ. Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 477-96. [DOI: 10.1007/978-1-4939-7677-5_23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Wu WK, Chen CC, Panyod S, Chen RA, Wu MS, Sheen LY, Chang SC. Optimization of fecal sample processing for microbiome study - The journey from bathroom to bench. J Formos Med Assoc 2019;118:545-55. [PMID: 29490879 DOI: 10.1016/j.jfma.2018.02.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
15 Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res 2017;179:204-22. [PMID: 27591027 DOI: 10.1016/j.trsl.2016.08.002] [Cited by in Crossref: 238] [Cited by in F6Publishing: 202] [Article Influence: 39.7] [Reference Citation Analysis]
16 Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med 2017;177:784-91. [PMID: 28346595 DOI: 10.1001/jamainternmed.2017.0212] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 14.6] [Reference Citation Analysis]
17 Mailhe M, Ricaboni D, Vitton V, Gonzalez JM, Bachar D, Dubourg G, Cadoret F, Robert C, Delerce J, Levasseur A, Fournier PE, Angelakis E, Lagier JC, Raoult D. Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing. BMC Microbiol 2018;18:157. [PMID: 30355340 DOI: 10.1186/s12866-018-1304-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
18 Moran-Ramos S, López-Contreras BE, Canizales-Quinteros S. Gut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality? Arch Med Res 2017;48:735-53. [PMID: 29292011 DOI: 10.1016/j.arcmed.2017.11.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
19 Hufnagl K, Pali-Schöll I, Roth-Walter F, Jensen-Jarolim E. Dysbiosis of the gut and lung microbiome has a role in asthma. Semin Immunopathol 2020;42:75-93. [PMID: 32072252 DOI: 10.1007/s00281-019-00775-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
20 Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care 2022;12:3. [PMID: 34985651 DOI: 10.1186/s13613-021-00976-5] [Reference Citation Analysis]
21 Martin TC, Visconti A, Spector TD, Falchi M. Conducting metagenomic studies in microbiology and clinical research. Appl Microbiol Biotechnol 2018;102:8629-46. [PMID: 30078138 DOI: 10.1007/s00253-018-9209-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
22 Haderer M, Neubert P, Rinner E, Scholtis A, Broncy L, Gschwendtner H, Kandulski A, Pavel V, Mehrl A, Brochhausen C, Schlosser S, Gülow K, Kunst C, Müller M. Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases. Gut 2021:gutjnl-2020-321663. [PMID: 33707230 DOI: 10.1136/gutjnl-2020-321663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Drew DA, Chan AT. Aspirin in the Prevention of Colorectal Neoplasia. Annu Rev Med 2021;72:415-30. [PMID: 33035431 DOI: 10.1146/annurev-med-060319-120913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
24 Desbuissons G, Deray G, Mercadal L. [Proton pump inhibitors and kidney]. Nephrol Ther 2018;14 Suppl 1:S115-24. [PMID: 29274872 DOI: 10.1016/j.nephro.2017.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Yoshida N, Yamashita T, Hirata KI. Gut Microbiome and Cardiovascular Diseases. Diseases 2018;6:E56. [PMID: 29966270 DOI: 10.3390/diseases6030056] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
26 [DOI: 10.1101/2020.07.12.20151084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Davenport ER, Goodrich JK, Bell JT, Spector TD, Ley RE, Clark AG. ABO antigen and secretor statuses are not associated with gut microbiota composition in 1,500 twins. BMC Genomics 2016;17:941. [PMID: 27871240 DOI: 10.1186/s12864-016-3290-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
28 Nava Lara RA, Aguilera-Mendoza L, Brizuela CA, Peña A, Del Rio G. Heterologous Machine Learning for the Identification of Antimicrobial Activity in Human-Targeted Drugs. Molecules 2019;24:E1258. [PMID: 30935109 DOI: 10.3390/molecules24071258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
29 Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
30 Guo Y, Du Y, Xie L, Pu Y, Yuan J, Wang Z, Zhang T, Wang B. Effects of Paeonol and Gastroretention Tablets of Paeonol on Experimental Gastric Ulcers and Intestinal Flora in Rats. Inflammation 2020;43:2178-90. [PMID: 32642910 DOI: 10.1007/s10753-020-01285-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
32 Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306. [PMID: 30196156 DOI: 10.1016/j.cgh.2018.08.065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
33 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
34 El Sayed R, Haibe Y, Amhaz G, Bouferraa Y, Shamseddine A. Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? Int J Mol Sci 2021;22:2142. [PMID: 33670011 DOI: 10.3390/ijms22042142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lundgren D, Eklöf V, Palmqvist R, Hultdin J, Karling P. Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy. Scand J Gastroenterol 2019;54:152-7. [PMID: 30676120 DOI: 10.1080/00365521.2019.1566493] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
36 Fei N, Bernabé BP, Lie L, Baghdan D, Bedu-Addo K, Plange-Rhule J, Forrester TE, Lambert EV, Bovet P, Gottel N, Riesen W, Korte W, Luke A, Kliethermes SA, Layden BT, Gilbert JA, Dugas LR. The human microbiota is associated with cardiometabolic risk across the epidemiologic transition. PLoS One 2019;14:e0215262. [PMID: 31339887 DOI: 10.1371/journal.pone.0215262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
37 Beaumont M, Goodrich JK, Jackson MA, Yet I, Davenport ER, Vieira-Silva S, Debelius J, Pallister T, Mangino M, Raes J, Knight R, Clark AG, Ley RE, Spector TD, Bell JT. Heritable components of the human fecal microbiome are associated with visceral fat. Genome Biol 2016;17:189. [PMID: 27666579 DOI: 10.1186/s13059-016-1052-7] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 18.2] [Reference Citation Analysis]
38 Latour K, Huang TD, Jans B, Berhin C, Bogaerts P, Noel A, Nonhoff C, Dodémont M, Denis O, Ieven M, Loens K, Schoevaerdts D, Catry B, Glupczynski Y. Prevalence of multidrug-resistant organisms in nursing homes in Belgium in 2015. PLoS One 2019;14:e0214327. [PMID: 30921364 DOI: 10.1371/journal.pone.0214327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
39 van Dorst JM, Tam RY, Ooi CY. What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics? Nutrients 2022;14:480. [DOI: 10.3390/nu14030480] [Reference Citation Analysis]
40 Oh TG, Kim SM, Atkins AR, Yu RT, Downes M, Evans RM, Loomba R. Proton pump inhibitor use status does not modify the microbiome signature for cirrhosis. Cell Metab 2021;33:457. [PMID: 33657386 DOI: 10.1016/j.cmet.2021.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhao Y, Yang Y, Aruna, Xiao J, Song J, Huang T, Li S, Kou J, Huang L, Ji D, Xiong S, Peng W, Xu S, Cheng B. Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Front Med (Lausanne) 2021;8:776955. [PMID: 34869495 DOI: 10.3389/fmed.2021.776955] [Reference Citation Analysis]
42 Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Hayashi K, Goto H, Hirooka Y. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int 2019;13:234-44. [DOI: 10.1007/s12072-019-09932-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
43 Yang L, Bajinka O, Jarju PO, Tan Y, Taal AM, Ozdemir G. The varying effects of antibiotics on gut microbiota. AMB Express 2021;11:116. [PMID: 34398323 DOI: 10.1186/s13568-021-01274-w] [Reference Citation Analysis]
44 D'Souza SM, Houston K, Keenan L, Yoo BS, Parekh PJ, Johnson DA. Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: A paradigm shift from acid to bacteria? World J Gastroenterol 2021; 27(18): 2054-2072 [PMID: 34025064 DOI: 10.3748/wjg.v27.i18.2054] [Reference Citation Analysis]
45 Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors. Front Immunol 2021;12:716317. [PMID: 34777340 DOI: 10.3389/fimmu.2021.716317] [Reference Citation Analysis]
46 Sun J, Zhao F, Lin B, Feng J, Wu X, Liu Y, Zhao L, Zhu B, Wei Y. Gut Microbiota Participates in Antithyroid Drug Induced Liver Injury Through the Lipopolysaccharide Related Signaling Pathway. Front Pharmacol 2020;11:598170. [PMID: 33390986 DOI: 10.3389/fphar.2020.598170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Watanabe K, Shimodaira Y, Takahashi S, Fukuda S, Koizumi S, Matsuhashi T, Iijima K. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection. Am J Gastroenterol 2021;116:1632-7. [PMID: 33989224 DOI: 10.14309/ajg.0000000000001309] [Reference Citation Analysis]
48 Koulouridi A, Messaritakis I, Gouvas N, Tsiaoussis J, Souglakos J. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer. Cancers (Basel) 2020;13:E43. [PMID: 33375686 DOI: 10.3390/cancers13010043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Zhou J, Shrestha P, Qiu Z, Harman DG, Teoh WC, Al-Sohaily S, Liem H, Turner I, Ho V. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinoma. J Clin Med. 2020;9. [PMID: 32650561 DOI: 10.3390/jcm9072162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Jordakieva G, Kundi M, Untersmayr E, Pali-Schöll I, Reichardt B, Jensen-Jarolim E. Country-wide medical records infer increased allergy risk of gastric acid inhibition. Nat Commun 2019;10:3298. [PMID: 31363098 DOI: 10.1038/s41467-019-10914-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
51 Horvath A, Stadlbauer V. [Proton Pump Inhibitors and their Microbiome-Mediated Side Effects]. Zentralbl Chir 2021;146:165-9. [PMID: 33327006 DOI: 10.1055/a-1312-7587] [Reference Citation Analysis]
52 Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, Zhong H, Liu Z, Gao Y, Zhao H, Zhang D, Su Z, Fang Z, Lan Z, Li J, Xiao L, Li J, Li R, Li X, Li F, Ren H, Huang Y, Peng Y, Li G, Wen B, Dong B, Chen JY, Geng QS, Zhang ZW, Yang H, Wang J, Wang J, Zhang X, Madsen L, Brix S, Ning G, Xu X, Liu X, Hou Y, Jia H, He K, Kristiansen K. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. [PMID: 29018189 DOI: 10.1038/s41467-017-00900-1] [Cited by in Crossref: 424] [Cited by in F6Publishing: 400] [Article Influence: 84.8] [Reference Citation Analysis]
53 Olshan KL, Zomorrodi AR, Pujolassos M, Troisi J, Khan N, Fanelli B, Kenyon V, Fasano A, Leonard MM. Microbiota and Metabolomic Patterns in the Breast Milk of Subjects with Celiac Disease on a Gluten-Free Diet. Nutrients 2021;13:2243. [PMID: 34210038 DOI: 10.3390/nu13072243] [Reference Citation Analysis]
54 Wauters L, Talley NJ, Walker MM, Tack J, Vanuytsel T. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut 2020;69:591-600. [DOI: 10.1136/gutjnl-2019-318536] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
55 Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD, Ang TL. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore. Singapore Med J 2019;60:512-21. [PMID: 30488079 DOI: 10.11622/smedj.2018152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
56 Yang J, Wu J, Li Y, Zhang Y, Cho WC, Ju X, van Schothorst EM, Zheng Y. Gut bacteria formation and influencing factors. FEMS Microbiol Ecol 2021;97:fiab043. [PMID: 33705527 DOI: 10.1093/femsec/fiab043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Wang X, Wu M. Research progress of gut microbiota and frailty syndrome. Open Med (Wars) 2021;16:1525-36. [PMID: 34712824 DOI: 10.1515/med-2021-0364] [Reference Citation Analysis]
58 Mima K, Ogino S, Nakagawa S, Sawayama H, Kinoshita K, Krashima R, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Sakamoto Y, Yamashita YI, Yoshida N, Chikamoto A, Ishiko T, Baba H. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol 2017;26:368-76. [PMID: 29113654 DOI: 10.1016/j.suronc.2017.07.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
59 Bouferraa Y, Chedid A, Amhaz G, El Lakkiss A, Mukherji D, Temraz S, Shamseddine A. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. Int J Mol Sci 2021;22:8036. [PMID: 34360802 DOI: 10.3390/ijms22158036] [Reference Citation Analysis]
60 Van Biervliet S, Hauser B, Verhulst S, Stepman H, Delanghe J, Warzee JP, Pot B, Vandewiele T, Wilschanski M. Probiotics in cystic fibrosis patients: A double blind crossover placebo controlled study: Pilot study from the ESPGHAN Working Group on Pancreas/CF. Clin Nutr ESPEN 2018;27:59-65. [PMID: 30144894 DOI: 10.1016/j.clnesp.2018.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
61 Verdi S, Abbasian G, Bowyer RCE, Lachance G, Yarand D, Christofidou P, Mangino M, Menni C, Bell JT, Falchi M, Small KS, Williams FMK, Hammond CJ, Hart DJ, Spector TD, Steves CJ. TwinsUK: The UK Adult Twin Registry Update. Twin Res Hum Genet 2019;22:523-9. [DOI: 10.1017/thg.2019.65] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
62 Shah A, Talley NJ, Koloski N, Macdonald GA, Kendall BJ, Shanahan ER, Walker MM, Keely S, Jones MP, Morrison M, Holtmann GJ. Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:155-67. [PMID: 32412673 DOI: 10.1111/apt.15786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
63 Bowyer RCE, Twohig-Bennett C, Coombes E, Wells PM, Spector TD, Jones AP, Steves CJ. Microbiota composition is moderately associated with greenspace composition in a UK cohort of twins. Sci Total Environ 2021;:152321. [PMID: 34915018 DOI: 10.1016/j.scitotenv.2021.152321] [Reference Citation Analysis]
64 Parsons E, Claud K, Petrof EO. The infant microbiome and implications for central nervous system development. Prog Mol Biol Transl Sci 2020;171:1-13. [PMID: 32475519 DOI: 10.1016/bs.pmbts.2020.04.007] [Reference Citation Analysis]
65 Yap TW, Leow AH, Azmi AN, Callahan DL, Perez-Perez GI, Loke MF, Goh KL, Vadivelu J. Global Fecal and Plasma Metabolic Dynamics Related to Helicobacter pylori Eradication. Front Microbiol 2017;8:536. [PMID: 28424674 DOI: 10.3389/fmicb.2017.00536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
66 Basak M, Mahata T, Chakraborti S, Kumar P, Bhattacharya B, Bandyopadhyay SK, Das M, Stewart A, Saha S, Maity B. Malabaricone C Attenuates Nonsteroidal Anti-Inflammatory Drug-Induced Gastric Ulceration by Decreasing Oxidative/Nitrative Stress and Inflammation and Promoting Angiogenic Autohealing. Antioxid Redox Signal 2020;32:766-84. [PMID: 31830804 DOI: 10.1089/ars.2019.7781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Babic A, Zhang X, Morales-Oyarvide V, Yuan C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, Wu K, Fuchs CS, Giovannucci EL, Stampfer MJ, Ng K. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer 2020;123:844-51. [PMID: 32541871 DOI: 10.1038/s41416-020-0939-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
68 Zhou Y, Ye Z, Lu J, Miao S, Lu X, Sun H, Wu J, Wang Y, Huang Y. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. Helicobacter 2020;25:e12721. [PMID: 32656891 DOI: 10.1111/hel.12721] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 Espinoza JL, Matsumoto A, Tanaka H, Matsumura I. Gastric microbiota: An emerging player in Helicobacter pylori-induced gastric malignancies. Cancer Lett. 2018;414:147-152. [PMID: 29138097 DOI: 10.1016/j.canlet.2017.11.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
70 Nkansa-Gyamfi NA, Kazibwe J, Traore DAK, Nji E. Prevalence of multidrug-, extensive drug-, and pandrug-resistant commensal Escherichia coli isolated from healthy humans in community settings in low- and middle-income countries: a systematic review and meta-analysis. Glob Health Action 2019;12:1815272. [PMID: 32909519 DOI: 10.1080/16549716.2020.1815272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
71 Samarkos M, Mastrogianni E, Kampouropoulou O. The role of gut microbiota in Clostridium difficile infection. Eur J Intern Med 2018;50:28-32. [PMID: 29428498 DOI: 10.1016/j.ejim.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
72 Drall KM, Tun HM, Kozyrskyj AL. Commentary: The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study. Front Cell Infect Microbiol 2018;8:430. [PMID: 30619776 DOI: 10.3389/fcimb.2018.00430] [Reference Citation Analysis]
73 Houghton LA, Lee AS, Badri H, DeVault KR, Smith JA. Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nat Rev Gastroenterol Hepatol 2016;13:445-60. [PMID: 27381074 DOI: 10.1038/nrgastro.2016.91] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
74 Hussain N, Naeem M, Pinato DJ. Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? Hum Vaccin Immunother 2021;17:55-61. [PMID: 32574106 DOI: 10.1080/21645515.2020.1769398] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
75 Cheung KS, Lam LK, Seto WK, Leung WK. Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma. Liver Cancer 2021;10:606-14. [PMID: 34950183 DOI: 10.1159/000518090] [Reference Citation Analysis]
76 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
77 Nowak RG, Bentzen SM, Ravel J, Crowell TA, Dauda W, Ma B, Liu H, Blattner WA, Baral SD, Charurat ME; TRUST/RV368 Study Group. Anal Microbial Patterns and Oncogenic Human Papillomavirus in a Pilot Study of Nigerian Men Who Have Sex with Men at Risk for or Living with HIV. AIDS Res Hum Retroviruses 2019;35:267-75. [PMID: 30215262 DOI: 10.1089/AID.2018.0158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
78 Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer 2021;9:e002421. [PMID: 33827906 DOI: 10.1136/jitc-2021-002421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
79 Mohandas S, Soma VL, Tran TDB, Sodergren E, Ambooken T, Goldman DL, Weinstock G, Herold BC. Differences in Gut Microbiome in Hospitalized Immunocompetent vs. Immunocompromised Children, Including Those With Sickle Cell Disease. Front Pediatr 2020;8:583446. [PMID: 33282798 DOI: 10.3389/fped.2020.583446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer 2021. [PMID: 34711947 DOI: 10.1038/s41416-021-01606-4] [Reference Citation Analysis]
81 Sultan AA, Mallen C, Muller S, Hider S, Scott I, Helliwell T, Hall LJ. Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study. BMC Med 2019;17:154. [PMID: 31387605 DOI: 10.1186/s12916-019-1394-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
82 Chuang S, Lin C, Peng C, Huang W, Su W, Lai S, Lai H. Proton pump inhibitors increase the risk of cholecystitis: a population-based case–control study. Gut 2019;68:1337-9. [DOI: 10.1136/gutjnl-2018-316899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
83 Konturek PC, Zopf Y. Therapeutische Modulation der Darmmikrobiota beim Reizdarmsyndrom: Von Probiotika bis zur fäkalen Mikrobiota-Therapie. MMW - Fortschritte der Medizin 2017;159:1-5. [DOI: 10.1007/s15006-017-0338-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
84 Birkeland E, Gharagozlian S, Birkeland KI, Holm OKS, Thorsby PM, Aas AM. Effect of inulin-type fructans on appetite in patients with type 2 diabetes: a randomised controlled crossover trial. J Nutr Sci 2021;10:e72. [PMID: 34589204 DOI: 10.1017/jns.2021.70] [Reference Citation Analysis]
85 Kulecka M, Fraczek B, Mikula M, Zeber-Lubecka N, Karczmarski J, Paziewska A, Ambrozkiewicz F, Jagusztyn-Krynicka K, Cieszczyk P, Ostrowski J. The composition and richness of the gut microbiota differentiate the top Polish endurance athletes from sedentary controls. Gut Microbes 2020;11:1374-84. [PMID: 32401138 DOI: 10.1080/19490976.2020.1758009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, Ren S, Chen X, Zhou C. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2019;130:10-7. [DOI: 10.1016/j.lungcan.2019.01.017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 17.3] [Reference Citation Analysis]
87 Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623-628. [PMID: 29555994 DOI: 10.1038/nature25979] [Cited by in Crossref: 709] [Cited by in F6Publishing: 602] [Article Influence: 177.3] [Reference Citation Analysis]
88 Ross CL, Spinler JK, Savidge TC. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Anaerobe 2016;41:37-43. [PMID: 27180006 DOI: 10.1016/j.anaerobe.2016.05.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
89 Chen Y, Liu B, Glass K, Du W, Banks E, Kirk M. Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis. PLoS One 2016;11:e0168618. [PMID: 27997598 DOI: 10.1371/journal.pone.0168618] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
90 Paroni Sterbini F, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, Bugli F, Martini C, Ricciardi W, Gasbarrini A, Sanguinetti M, Cammarota G, Posteraro B. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Appl Environ Microbiol. 2016;82:6633-6644. [PMID: 27590821 DOI: 10.1128/aem.01437-16] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
91 Wurm P, Spindelboeck W, Krause R, Plank J, Fuchs G, Bashir M, Petritsch W, Halwachs B, Langner C, Högenauer C, Gorkiewicz G. Antibiotic-Associated Apoptotic Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion. Crit Care Med 2017;45:e600-6. [PMID: 28333760 DOI: 10.1097/CCM.0000000000002310] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
92 Zhang J, Che H, Zhang B, Zhang C, Zhou B, Ji H, Xie J, Shi X, Li X, Wang F, Tang X. JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study. Phytomedicine 2021;88:153584. [PMID: 34119741 DOI: 10.1016/j.phymed.2021.153584] [Reference Citation Analysis]
93 Pérez-ruiz E, Jiménez-castro J, Berciano-guerrero M, Valdivia J, Estalella-mendoza S, Toscano F, Rodriguez de la Borbolla Artacho M, Garrido-siles M, Martínez-bautista MJ, Villatoro Roldan R, Rivas-ruiz F, Nogales-fernández E, Morales C, Pérez-valderrama B, De la Cruz-merino L, Rueda A. Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. Clin Transl Oncol 2020;22:1778-85. [DOI: 10.1007/s12094-020-02315-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Rashidi A, Weisdorf DJ. Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. Transl Res 2020;220:167-81. [PMID: 32275896 DOI: 10.1016/j.trsl.2020.03.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
95 Cheng VCC, Chen JHK, So SYC, Wong SCY, Chau P, Wong LMW, Ching RHC, Ng MML, Lee W, Hung IFN, Ho P, Yuen K. A Novel Risk Factor Associated With Colonization by Carbapenemase-Producing Enterobacteriaceae: Use of Proton Pump Inhibitors in Addition to Antimicrobial Treatment. Infect Control Hosp Epidemiol 2016;37:1418-25. [DOI: 10.1017/ice.2016.202] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
96 Celiker H. A new proposed mechanism of action for gastric bypass surgery: Air hypothesis. Med Hypotheses. 2017;107:81-89. [PMID: 28915970 DOI: 10.1016/j.mehy.2017.08.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
97 Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW; Taiwan Acid-related Disease (TARD) Study Group. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter 2018;23:e12498. [PMID: 29897654 DOI: 10.1111/hel.12498] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
98 Chen C, Liu H, Duan R, Wang F, Duan L. The efficacy and safety of acid suppressants for gastrointestinal bleeding prophylaxis in cardiac care unit patients. J Gastroenterol Hepatol 2021;36:2131-40. [PMID: 33586808 DOI: 10.1111/jgh.15432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
100 Liu K, Lu C. Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy. Transl Cancer Res 2018;7:S608-10. [PMID: 30443490 DOI: 10.21037/tcr.2018.05.37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
101 Yuan J, Zhang C, Sparks JA, Malspeis S, Tsoi KK, Kim JH, Fisher BA, Gao F, Sumerlin T, Liu Y, Liu Y, Pan Y, He Y, Sung JJY. Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study. Aliment Pharmacol Ther 2020;52:449-58. [PMID: 32598046 DOI: 10.1111/apt.15834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Ma X, Huang L, Huang Z, Jiang J, Zhao C, Tong H, Feng Z, Gao J, Liu R, Zhang M, Zhou M, Tan Q, Liu L, Tang C. The impacts of acid suppression on duodenal microbiota during the early phase of severe acute pancreatitis. Sci Rep 2020;10:20063. [PMID: 33208878 DOI: 10.1038/s41598-020-77245-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. BMC Cancer 2020;20:383. [PMID: 32375706 DOI: 10.1186/s12885-020-06882-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
104 Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker MG, Nigro O, Tanda E, Russo A. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol 2019;142:26-34. [PMID: 31352168 DOI: 10.1016/j.critrevonc.2019.07.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
105 Jiménez-Avalos JA, Arrevillaga-Boni G, González-López L, García-Carvajal ZY, González-Avila M. Classical methods and perspectives for manipulating the human gut microbial ecosystem. Crit Rev Food Sci Nutr 2021;61:234-58. [PMID: 32114770 DOI: 10.1080/10408398.2020.1724075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
106 Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer 2020;8:e001361. [PMID: 33154150 DOI: 10.1136/jitc-2020-001361] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
107 Lin HC, Huang KT, Lin HL, Uang YS, Ho Y, Keller JJ, Wang LH. Use of gastric acid-suppressive agents increases the risk of dementia in patients with upper gastrointestinal disease: A population-based retrospective cohort study. PLoS One 2021;16:e0249050. [PMID: 33765029 DOI: 10.1371/journal.pone.0249050] [Reference Citation Analysis]
108 Sun S, Ye W, Zhao R, Hu J, Zhang X, Yang M, Zhao H, Sheng J. Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study. Front Med (Lausanne) 2021;8:763370. [PMID: 34859015 DOI: 10.3389/fmed.2021.763370] [Reference Citation Analysis]
109 Snider EJ, Freedberg DE, Abrams JA. Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci. 2016;61:2217-2225. [PMID: 27068172 DOI: 10.1007/s10620-016-4155-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
110 Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51:505-526. [PMID: 31990420 DOI: 10.1111/apt.15604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
111 Robinson LB, Camargo CA Jr. Acid suppressant medications and the risk of allergic diseases. Expert Rev Clin Immunol 2018;14:771-80. [PMID: 30113236 DOI: 10.1080/1744666X.2018.1512405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
112 Ducarmon QR, Zwittink RD, Hornung BVH, van Schaik W, Young VB, Kuijper EJ. Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection. Microbiol Mol Biol Rev 2019;83:e00007-19. [PMID: 31167904 DOI: 10.1128/MMBR.00007-19] [Cited by in Crossref: 78] [Cited by in F6Publishing: 48] [Article Influence: 26.0] [Reference Citation Analysis]
113 Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2017;19:42. [PMID: 28733944 DOI: 10.1007/s11894-017-0577-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
114 Castellani C, Singer G, Kashofer K, Huber-Zeyringer A, Flucher C, Kaiser M, Till H. The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study. Front Cell Infect Microbiol. 2017;7:444. [PMID: 29075620 DOI: 10.3389/fcimb.2017.00444] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
115 Kim JW, Jeong Y, Park SJ, Jin H, Lee J, Ju JH, Ji GE, Park SH. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford) 2021;60:708-16. [PMID: 32789440 DOI: 10.1093/rheumatology/keaa316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Mcgovern AS, Hamlin AS, Winter G. A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. Aust N Z J Psychiatry 2019;53:1151-66. [DOI: 10.1177/0004867419877954] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
117 Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153:35-48. [PMID: 28528705 DOI: 10.1053/j.gastro.2017.04.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 146] [Article Influence: 39.6] [Reference Citation Analysis]
118 Haibe Y, El Husseini Z, El Sayed R, Shamseddine A. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. Int J Mol Sci 2020;21:E6176. [PMID: 32867025 DOI: 10.3390/ijms21176176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
119 Willems RPJ, van Dijk K, Ket JCF, Vandenbroucke-Grauls CMJE. Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms: A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:561-71. [PMID: 32091544 DOI: 10.1001/jamainternmed.2020.0009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
120 Lin YT, Lin TY, Hung SC, Liu PY, Hung WC, Tsai WC, Tsai YC, Delicano RA, Chuang YS, Kuo MC, Chiu YW, Wu PH. Differences in the Microbial Composition of Hemodialysis Patients Treated with and without β-Blockers. J Pers Med 2021;11:198. [PMID: 33809103 DOI: 10.3390/jpm11030198] [Reference Citation Analysis]
121 Ortiz AM, Flynn JK, DiNapoli SR, Sortino O, Vujkovic-Cvijin I, Belkaid Y, Sereti I, Brenchley JM. Antiretroviral Therapy Administration in Healthy Rhesus Macaques Is Associated with Transient Shifts in Intestinal Bacterial Diversity and Modest Immunological Perturbations. J Virol 2019;93:e00472-19. [PMID: 31270225 DOI: 10.1128/JVI.00472-19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
122 Rajilic-Stojanovic M, Figueiredo C, Smet A, Hansen R, Kupcinskas J, Rokkas T, Andersen L, Machado JC, Ianiro G, Gasbarrini A, Leja M, Gisbert JP, Hold GL. Systematic review: gastric microbiota in health and disease. Aliment Pharmacol Ther 2020;51:582-602. [PMID: 32056247 DOI: 10.1111/apt.15650] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 21.5] [Reference Citation Analysis]
123 Lee C, Hong SN. Does Long-Term Proton Pump Inhibitor Therapy Affect the Health of Gut Microbiota? Gut Liver 2016;10:865-6. [PMID: 27784840 DOI: 10.5009/gnl16438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
124 Tan TC, Noviani M, Leung YY, Low AHL. The microbiome and systemic sclerosis: A review of current evidence. Best Pract Res Clin Rheumatol 2021;35:101687. [PMID: 33849778 DOI: 10.1016/j.berh.2021.101687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Maccioni L, Gao B, Leclercq S, Pirlot B, Horsmans Y, De Timary P, Leclercq I, Fouts D, Schnabl B, Stärkel P. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes 2020;12:1782157. [PMID: 32588725 DOI: 10.1080/19490976.2020.1782157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
126 Schubert ML. Gastric acid secretion. Curr Opin Gastroenterol 2016;32:452-60. [PMID: 27607343 DOI: 10.1097/MOG.0000000000000308] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
127 Maksimaityte V, Bausys A, Kryzauskas M, Luksta M, Stundiene I, Bickaite K, Bausys B, Poskus T, Bausys R, Strupas K. Gastrectomy impact on the gut microbiome in patients with gastric cancer: A comprehensive review. World J Gastrointest Surg 2021; 13(7): 678-688 [PMID: 34354801 DOI: 10.4240/wjgs.v13.i7.678] [Reference Citation Analysis]
128 Jagdish BR, Kilgore WR 3rd. The Relationship Between Functional Dyspepsia, PPI Therapy, and the Gastric Microbiome. Kans J Med 2021;14:136-40. [PMID: 34084274 DOI: 10.17161/kjm.vol1414831] [Reference Citation Analysis]
129 Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, Mujagic Z, Jonkers DMAE, Masclee AAM, Fu J, Kurilshikov A, Wijmenga C, Zhernakova A, Weersma RK. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362. [PMID: 31953381 DOI: 10.1038/s41467-019-14177-z] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 51.5] [Reference Citation Analysis]
130 Luo Z, Alekseyenko AV, Ogunrinde E, Li M, Li QZ, Huang L, Tsao BP, Kamen DL, Oates JC, Li Z, Gilkeson GS, Jiang W. Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery in Clinic. Front Microbiol 2020;11:613268. [PMID: 33488555 DOI: 10.3389/fmicb.2020.613268] [Reference Citation Analysis]
131 Lewis DS, Lee T, Konanur M, Ziegler C, Hall MD, Pabon-ramos WM, Suhocki PV, Smith TP, Kim CY, Choi SS, Ronald J. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology 2019;30:163-9. [DOI: 10.1016/j.jvir.2018.10.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
132 Lin TY, Hung SC. Association of subjective global assessment of nutritional status with gut microbiota in hemodialysis patients: a case-control study. Nephrol Dial Transplant 2021;36:1104-11. [PMID: 32240309 DOI: 10.1093/ndt/gfaa019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Le Roy CI, Bowyer RCE, Castillo-Fernandez JE, Pallister T, Menni C, Steves CJ, Berry SE, Spector TD, Bell JT. Dissecting the role of the gut microbiota and diet on visceral fat mass accumulation. Sci Rep 2019;9:9758. [PMID: 31278309 DOI: 10.1038/s41598-019-46193-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
134 Xia B, Yang M, Nguyen LH, He Q, Zhen J, Yu Y, Di M, Qin X, Lu K, Kuo ZC, He Y, Zhang C, Meng W, Yuan J. Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. Gastroenterology 2021:S0016-5085(21)03350-3. [PMID: 34389338 DOI: 10.1053/j.gastro.2021.08.005] [Reference Citation Analysis]
135 Fart F, Rajan SK, Wall R, Rangel I, Ganda-Mall JP, Tingö L, Brummer RJ, Repsilber D, Schoultz I, Lindqvist CM. Differences in Gut Microbiome Composition between Senior Orienteering Athletes and Community-Dwelling Older Adults. Nutrients 2020;12:E2610. [PMID: 32867153 DOI: 10.3390/nu12092610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Noh K, Kang YR, Nepal MR, Shakya R, Kang MJ, Kang W, Lee S, Jeong HG, Jeong TC. Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs. Arch Pharm Res 2017;40:1345-55. [PMID: 29181640 DOI: 10.1007/s12272-017-0986-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
137 Olekhnovich EI, Manolov AI, Samoilov AE, Prianichnikov NA, Malakhova MV, Tyakht AV, Pavlenko AV, Babenko VV, Larin AK, Kovarsky BA, Starikova EV, Glushchenko OE, Safina DD, Markelova MI, Boulygina EA, Khusnutdinova DR, Malanin SY, Abdulkhakov SR, Abdulkhakov RA, Grigoryeva TV, Kostryukova ES, Govorun VM, Ilina EN. Shifts in the Human Gut Microbiota Structure Caused by Quadruple Helicobacter pylori Eradication Therapy. Front Microbiol 2019;10:1902. [PMID: 31507546 DOI: 10.3389/fmicb.2019.01902] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
138 Li M, Zeng C, Yao J, Ge Y, An G. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. Int Immunopharmacol 2020;88:106972. [PMID: 33182025 DOI: 10.1016/j.intimp.2020.106972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
139 Wang Y, Liu F, Zhang G, Su Y, Sun X, Chen Q, Wang C, Fu H, He Y, Zhu X, Liu X, Lv M, Zhao X, Zhao X, Li Y, Wang Q, Huang X, Zhang X. Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia. Sci China Life Sci 2021;64:766-83. [PMID: 32857289 DOI: 10.1007/s11427-020-1788-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Yoshihara T, Oikawa Y, Kato T, Kessoku T, Kobayashi T, Kato S, Misawa N, Ashikari K, Fuyuki A, Ohkubo H, Higurashi T, Tateishi Y, Tanaka Y, Nakajima S, Ohno H, Wada K, Nakajima A. The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin. Gut Microbes 2020;11:1385-404. [PMID: 32515658 DOI: 10.1080/19490976.2020.1758290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
141 Ishioka M, Watanabe N, Sawaguchi M, Fukuda S, Shiga H, Matsuhashi T, Jin M, Iijima K. Phlegmonous Gastritis: A Report of Three Cases with Clinical and Imaging Features. Intern Med 2018;57:2185-8. [PMID: 29607969 DOI: 10.2169/internalmedicine.0707-17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
142 Kelly BJ, Tebas P. Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. Chest. 2018;153:266-277. [PMID: 28923757 DOI: 10.1016/j.chest.2017.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
143 Gaucher L, Adda L, Séjourné A, Joachim C, Guillaume C, Poulet C, Liabeuf S, Gras-Champel V, Masmoudi K, Houessinon A, Bennis Y, Batteux B. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol 2021;13:17588359211000591. [PMID: 33796151 DOI: 10.1177/17588359211000591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Schmid SM, Suchodolski JS, Price JM, Tolbert MK. Omeprazole Minimally Alters the Fecal Microbial Community in Six Cats: A Pilot Study. Front Vet Sci 2018;5:79. [PMID: 29713638 DOI: 10.3389/fvets.2018.00079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
145 Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91-7. [PMID: 29097494 DOI: 10.1126/science.aan3706] [Cited by in Crossref: 1735] [Cited by in F6Publishing: 1606] [Article Influence: 347.0] [Reference Citation Analysis]
146 Jackson MA, Bell JT, Spector TD, Steves CJ. A heritability-based comparison of methods used to cluster 16S rRNA gene sequences into operational taxonomic units. PeerJ 2016;4:e2341. [PMID: 27635321 DOI: 10.7717/peerj.2341] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
147 Zhang X, Han Y, Huang W, Jin M, Gao Z. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B 2021;11:1789-812. [PMID: 34386321 DOI: 10.1016/j.apsb.2020.09.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Lenoir C, El Biali M, Luthy C, Grosgurin O, Desmeules JA, Rollason V. Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more? Int J Clin Pharm 2019;41:1634-41. [DOI: 10.1007/s11096-019-00929-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
149 Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Nalluri H, Kaiser T, Holtan SG, Khoruts A, Weisdorf DJ, Staley C. Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome 2021;9:211. [PMID: 34702350 DOI: 10.1186/s40168-021-01170-2] [Reference Citation Analysis]
150 Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152:134-141. [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
151 Bosch S, Lemmen JP, Menezes R, van der Hulst R, Kuijvenhoven J, Stokkers PC, de Meij TG, de Boer NK. The influence of lifestyle factors on fecal volatile organic compound composition as measured by an electronic nose. J Breath Res 2019;13:046001. [PMID: 31170704 DOI: 10.1088/1752-7163/ab2775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
152 Kaan AMM, Kahharova D, Zaura E. Acquisition and establishment of the oral microbiota. Periodontol 2000 2021;86:123-41. [PMID: 33690935 DOI: 10.1111/prd.12366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
153 Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit. Am J Gastroenterol. 2016;111:1641-1648. [PMID: 27575714 DOI: 10.1038/ajg.2016.343] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
154 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
155 Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR, Kaakoush NO. Signatures within the esophageal microbiome are associated with host genetics, age, and disease. Microbiome 2018;6:227. [PMID: 30558669 DOI: 10.1186/s40168-018-0611-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
156 Mehta P, Nahass RG, Brunetti L. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis. Clin Infect Dis 2021;73:e62-8. [PMID: 32386313 DOI: 10.1093/cid/ciaa545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
157 Hsu P, Pan C, Kao JY, Tsay F, Peng N, Kao S, Chen Y, Tsai T, Wu D, Tsai K. Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. Journal of Gastroenterology and Hepatology 2019;34:1968-76. [DOI: 10.1111/jgh.14736] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
158 Goedert JJ. The microbiota and HIV: shedding light on dark matters. AIDS 2017;31:863-5. [PMID: 28272137 DOI: 10.1097/QAD.0000000000001410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
159 Reveles KR, Ryan CN, Chan L, Cosimi RA, Haynes WL. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut 2018;67:1369-70. [PMID: 28993417 DOI: 10.1136/gutjnl-2017-315306] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
160 Wirbel J, Zych K, Essex M, Karcher N, Kartal E, Salazar G, Bork P, Sunagawa S, Zeller G. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol 2021;22:93. [PMID: 33785070 DOI: 10.1186/s13059-021-02306-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
161 Erber AC, Cetin H, Berry D, Schernhammer ES. The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. Int J Neurosci 2020;130:727-35. [PMID: 31870202 DOI: 10.1080/00207454.2019.1702549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
162 Madison AA, Woody A, Bailey B, Lustberg MB, Ramaswamy B, Wesolowski R, Williams N, Reinbolt R, VanDeusen JB, Sardesai S, Malarkey WB, Kiecolt-Glaser JK. Cognitive problems of breast cancer survivors on proton pump inhibitors. J Cancer Surviv 2020;14:226-34. [PMID: 31933149 DOI: 10.1007/s11764-019-00815-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
163 Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Current Opinion in Gastroenterology 2017;33:430-8. [DOI: 10.1097/mog.0000000000000392] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
164 Allin KH, Moayyedi P. Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander? Gastroenterology 2021:S0016-5085(21)03478-8. [PMID: 34499912 DOI: 10.1053/j.gastro.2021.09.005] [Reference Citation Analysis]
165 Birkeland E, Gharagozlian S, Gulseth HL, Birkeland KI, Hartmann B, Holst JJ, Holst R, Aas AM. Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial. Diabet Med 2021;38:e14657. [PMID: 34297363 DOI: 10.1111/dme.14657] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Wong SH, Yu J. Proton-pump inhibitor use before fecal microbiota transplant: A wonder drug, a necessary evil, or a needless prescription? J Gastroenterol Hepatol 2020;35:913-4. [PMID: 32537754 DOI: 10.1111/jgh.15103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Menéndez R, Méndez R, Polverino E, Rosales-Mayor E, Amara-Elori I, Reyes S, Posadas T, Fernández-Barat L, Torres A. Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. Respir Res 2017;18:176. [PMID: 28964260 DOI: 10.1186/s12931-017-0659-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
168 Derwich M, Mitus-Kenig M, Pawlowska E. Orally Administered NSAIDs-General Characteristics and Usage in the Treatment of Temporomandibular Joint Osteoarthritis-A Narrative Review. Pharmaceuticals (Basel) 2021;14:219. [PMID: 33807930 DOI: 10.3390/ph14030219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
169 Barnet MB, Blinman P, Cooper W, Boyer MJ, Kao S, Goodnow CC. Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes. Bioessays 2018;40:e1800050. [PMID: 29869436 DOI: 10.1002/bies.201800050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
170 Wolpert LE, Snieder H, Jansonius NM, Utheim TP, Hammond CJ, Vehof J. Medication use and dry eye symptoms: A large, hypothesis-free, population-based study in the Netherlands. Ocul Surf 2021;22:1-12. [PMID: 34171471 DOI: 10.1016/j.jtos.2021.06.009] [Reference Citation Analysis]
171 Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. Ann Pharmacother 2021;:10600280211033938. [PMID: 34282636 DOI: 10.1177/10600280211033938] [Reference Citation Analysis]
172 Pereira-Marques J, Ferreira RM, Pinto-Ribeiro I, Figueiredo C. Helicobacter pylori Infection, the Gastric Microbiome and Gastric Cancer. Adv Exp Med Biol 2019;1149:195-210. [PMID: 31016631 DOI: 10.1007/5584_2019_366] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
173 Boeing T, de Souza P, da Silva LM, Gasparotto Junior A. Herbal Medicines in the Treatment of Dyspepsia: An Overview. Planta Med 2021. [PMID: 34474492 DOI: 10.1055/a-1580-7782] [Reference Citation Analysis]
174 [DOI: 10.1101/2021.01.14.21249458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Martin-Nuñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front Endocrinol (Lausanne) 2021;12:639856. [PMID: 34220702 DOI: 10.3389/fendo.2021.639856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Almonte AA, Rangarajan H, Yip D, Fahrer AM. How does the gut microbiome influence immune checkpoint blockade therapy? Immunol Cell Biol 2021;99:361-72. [PMID: 33147357 DOI: 10.1111/imcb.12423] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
177 Tao ZH, Han JX, Fang JY. Helicobacter pylori infection and eradication: Exploring their impacts on the gastrointestinal microbiota. Helicobacter 2020;25:e12754. [PMID: 32876377 DOI: 10.1111/hel.12754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
178 Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
179 Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, Guan XM, Cui YN, Su W. Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China. Dig Dis Sci 2019;64:1193-203. [PMID: 30535886 DOI: 10.1007/s10620-018-5411-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
180 Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361:k2179. [PMID: 29899036 DOI: 10.1136/bmj.k2179] [Cited by in Crossref: 393] [Cited by in F6Publishing: 330] [Article Influence: 98.3] [Reference Citation Analysis]
181 Iino C, Shimoyama T, Chinda D, Arai T, Chiba D, Nakaji S, Fukuda S. Infection of Helicobacter pylori and Atrophic Gastritis Influence Lactobacillus in Gut Microbiota in a Japanese Population. Front Immunol. 2018;9:712. [PMID: 29681906 DOI: 10.3389/fimmu.2018.00712] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
182 Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: What if the results are true? Cancer Epidemiology 2018;54:139-40. [DOI: 10.1016/j.canep.2018.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
183 Verdi S, Jackson MA, Beaumont M, Bowyer RCE, Bell JT, Spector TD, Steves CJ. An Investigation Into Physical Frailty as a Link Between the Gut Microbiome and Cognitive Health. Front Aging Neurosci 2018;10:398. [PMID: 30564113 DOI: 10.3389/fnagi.2018.00398] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
184 Yixia Y, Sripetchwandee J, Chattipakorn N, Chattipakorn SC. The alterations of microbiota and pathological conditions in the gut of patients with colorectal cancer undergoing chemotherapy. Anaerobe 2021;68:102361. [PMID: 33781900 DOI: 10.1016/j.anaerobe.2021.102361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
185 Hurtubise R, Hudson M, Gyger G, Wang M, Steele RJ, Baron M, Hoa S; Canadian Scleroderma Research Group (CSRG). Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. Respir Med 2021;185:106482. [PMID: 34089970 DOI: 10.1016/j.rmed.2021.106482] [Reference Citation Analysis]
186 Le Bastard Q, Berthelot L, Soulillou JP, Montassier E. Impact of non-antibiotic drugs on the human intestinal microbiome. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34225544 DOI: 10.1080/14737159.2021.1952075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Salvatore S, Abkari A, Cai W, Catto-Smith A, Cruchet S, Gottrand F, Hegar B, Lifschitz C, Ludwig T, Shah N, Staiano A, Szajewska H, Treepongkaruna S, Vandenplas Y. Review shows that parental reassurance and nutritional advice help to optimise the management of functional gastrointestinal disorders in infants. Acta Paediatr 2018. [PMID: 29710375 DOI: 10.1111/apa.14378] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
188 Le Bastard Q, Javaudin F, Montassier E. [Non-antibiotic drugs have large effect on the intestinal microbiota]. Med Sci (Paris) 2018;34:654-6. [PMID: 30230456 DOI: 10.1051/medsci/20183408008] [Reference Citation Analysis]
189 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
190 Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, Wijmenga C, Zhernakova A, Weersma RK. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351-358. [PMID: 28118083 DOI: 10.1080/19490976.2017.1284732] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 13.4] [Reference Citation Analysis]
191 Yuan J, He Q, Nguyen LH, Wong MCS, Huang J, Yu Y, Xia B, Tang Y, He Y, Zhang C. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2021;70:1070-7. [PMID: 32989021 DOI: 10.1136/gutjnl-2020-322557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
192 Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, Pimenta JR, Machado LM, Shimba DS, Peixoto RD. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol 2021;28:783-99. [PMID: 33546228 DOI: 10.3390/curroncol28010076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
193 Ihekweazu FD, Versalovic J. Development of the Pediatric Gut Microbiome: Impact on Health and Disease. Am J Med Sci 2018;356:413-23. [PMID: 30384950 DOI: 10.1016/j.amjms.2018.08.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
194 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
195 Mullane KM, Dubberke ER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant 2019;33:e13564. [PMID: 31002420 DOI: 10.1111/ctr.13564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
196 Horvath A, Rainer F, Bashir M, Leber B, Schmerboeck B, Klymiuk I, Groselj-Strele A, Durdevic M, Freedberg DE, Abrams JA, Fickert P, Stiegler P, Stadlbauer V. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep. 2019;9:12000. [PMID: 31427714 DOI: 10.1038/s41598-019-48352-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
197 DeClercq V, Nearing JT, Langille MGI. Investigation of the impact of commonly used medications on the oral microbiome of individuals living without major chronic conditions. PLoS One 2021;16:e0261032. [PMID: 34882708 DOI: 10.1371/journal.pone.0261032] [Reference Citation Analysis]
198 Li DK, Chung RT. Use of proton pump inhibitors in chronic liver diseases. Clin Liver Dis (Hoboken) 2017;10:148-51. [PMID: 30992776 DOI: 10.1002/cld.678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
199 García-Rayado G, Sostres C, Lanas A. Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. Expert Rev Clin Pharmacol 2017;10:875-88. [PMID: 28463532 DOI: 10.1080/17512433.2017.1324782] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
200 Baek YH, Kang EJ, Hong S, Park S, Kim JH, Shin JY. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors. Int J Cancer 2021. [PMID: 34877670 DOI: 10.1002/ijc.33892] [Reference Citation Analysis]
201 van Hemert S, Skonieczna-Żydecka K, Loniewski I, Szredzki P, Marlicz W. Microscopic colitis-microbiome, barrier function and associated diseases. Ann Transl Med 2018;6:39. [PMID: 29610731 DOI: 10.21037/atm.2017.03.83] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
202 Boban M, Zulj M, Persic V, Medved I, Zekanovic D, Vcev A. Prolonged utilization of proton pump inhibitors in patients with ischemic and valvular heart disease is associated with surgical treatments, weight loss and aggravates anemia. Int J Cardiol 2016;219:277-81. [PMID: 27343420 DOI: 10.1016/j.ijcard.2016.06.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
204 Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Am J Gastroenterol. 2018;113:1177-1186. [PMID: 29872220 DOI: 10.1038/s41395-018-0085-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 14.5] [Reference Citation Analysis]
205 Shi YC, Cai ST, Tian YP, Zhao HJ, Zhang YB, Chen J, Ren RR, Luo X, Peng LH, Sun G, Yang YS. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease. Genomics Proteomics Bioinformatics 2019;17:52-63. [PMID: 31028880 DOI: 10.1016/j.gpb.2018.12.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
206 Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. Hepatol Res 2019;49:232-8. [PMID: 30198141 DOI: 10.1111/hepr.13249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
207 Jahnke JR, Roach J, Azcarate-Peril MA, Thompson AL. Maternal precarity and HPA axis functioning shape infant gut microbiota and HPA axis development in humans. PLoS One 2021;16:e0251782. [PMID: 34015045 DOI: 10.1371/journal.pone.0251782] [Reference Citation Analysis]
208 Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep 2017;17:94. [PMID: 29039142 DOI: 10.1007/s11910-017-0802-6] [Cited by in Crossref: 205] [Cited by in F6Publishing: 185] [Article Influence: 41.0] [Reference Citation Analysis]
209 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
210 Jackson MA, Verdi S, Maxan ME, Shin CM, Zierer J, Bowyer RCE, Martin T, Williams FMK, Menni C, Bell JT, Spector TD, Steves CJ. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun 2018;9:2655. [PMID: 29985401 DOI: 10.1038/s41467-018-05184-7] [Cited by in Crossref: 185] [Cited by in F6Publishing: 165] [Article Influence: 46.3] [Reference Citation Analysis]
211 Wauters L, Burns G, Ceulemans M, Walker MM, Vanuytsel T, Keely S, Talley NJ. Duodenal inflammation: an emerging target for functional dyspepsia? Expert Opin Ther Targets 2020;24:511-23. [PMID: 32249629 DOI: 10.1080/14728222.2020.1752181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
212 Saqui-Salces M, Tsao AC, Gillilland MG 3rd, Merchant JL. Weight gain in mice on a high caloric diet and chronically treated with omeprazole depends on sex and genetic background. Am J Physiol Gastrointest Liver Physiol 2017;312:G15-23. [PMID: 27810953 DOI: 10.1152/ajpgi.00211.2016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
213 Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, Wettermark B, Ärnlöv J, Janmaat CJ, Lindholm B, Dekker FW, Coresh J, Grams ME, Carrero JJ. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology 2017;153:702-10. [PMID: 28583827 DOI: 10.1053/j.gastro.2017.05.046] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
214 Van Ameringen M, Turna J, Patterson B, Pipe A, Mao RQ, Anglin R, Surette MG. The gut microbiome in psychiatry: A primer for clinicians. Depress Anxiety 2019;36:1004-25. [PMID: 31356715 DOI: 10.1002/da.22936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
215 De Roo AC, Regenbogen SE. Clostridium difficile Infection: An Epidemiology Update. Clin Colon Rectal Surg 2020;33:49-57. [PMID: 32104156 DOI: 10.1055/s-0040-1701229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
216 Haraguchi M, Miuma S, Masumoto H, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Miyaaki H, Taura N, Nakao K. Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis. Hepatol Int 2019;13:482-9. [DOI: 10.1007/s12072-019-09963-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
217 Iino C, Shimoyama T. Impact of Helicobacter pylori infection on gut microbiota. World J Gastroenterol 2021; 27(37): 6224-6230 [PMID: 34712028 DOI: 10.3748/wjg.v27.i37.6224] [Reference Citation Analysis]
218 Bartolomaeus H, Markó L, Wilck N, Luft FC, Forslund SK, Muller DN. Precarious Symbiosis Between Host and Microbiome in Cardiovascular Health. Hypertension 2019;73:926-35. [PMID: 30905198 DOI: 10.1161/HYPERTENSIONAHA.119.11786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
219 Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res. 2018;11:361-374. [PMID: 29491719 DOI: 10.2147/jpr.s156938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
220 Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, Matsumoto K, Asaoka D, Takahashi T, Nomoto K, Yamashiro Y, Watanabe S. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors. Dig Dis Sci. 2018;63:2940-2949. [PMID: 29796911 DOI: 10.1007/s10620-018-5122-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
221 Doohan D, Rezkitha YAA, Waskito LA, Vilaichone R, Yamaoka Y, Miftahussurur M. Integrating microbiome, transcriptome and metabolome data to investigate gastric disease pathogenesis: a concise review. Expert Rev Mol Med 2021;23. [DOI: 10.1017/erm.2021.8] [Reference Citation Analysis]
222 Gommers LMM, Ederveen THA, van der Wijst J, Overmars-Bos C, Kortman GAM, Boekhorst J, Bindels RJM, de Baaij JHF, Hoenderop JGJ. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia. FASEB J 2019;33:11235-46. [PMID: 31299175 DOI: 10.1096/fj.201900839R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
223 Kellerer T, Brandl B, Büttner J, Lagkouvardos I, Hauner H, Skurk T. Impact of Laparoscopic Sleeve Gastrectomy on Gut Permeability in Morbidly Obese Subjects. Obes Surg 2019;29:2132-43. [PMID: 30903427 DOI: 10.1007/s11695-019-03815-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
224 Lu Y, Liu H, Yang K, Mao Y, Meng L, Yang L, Ouyang G, Liu W. A comprehensive update: gastrointestinal microflora, gastric cancer and gastric premalignant condition, and intervention by traditional Chinese medicine. J Zhejiang Univ Sci B 2022;23:1-18. [PMID: 35029085 DOI: 10.1631/jzus.B2100182] [Reference Citation Analysis]
225 Imperatore N, Tortora R, Testa A, Gerbino N, Caporaso N, Rispo A. Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet. J Gastroenterol 2018;53:507-16. [DOI: 10.1007/s00535-017-1381-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
226 Traini I, Menzies J, Hughes J, Leach ST, Krishnan U. Oesophageal atresia: The growth gap. World J Gastroenterol 2020; 26(12): 1262-1272 [PMID: 32256015 DOI: 10.3748/wjg.v26.i12.1262] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
227 Aydin S, Ozkul C, Yucel NT, Karaca H. Gut Microbiome Alteration after Reboxetine Administration in Type-1 Diabetic Rats. Microorganisms 2021;9:1948. [PMID: 34576843 DOI: 10.3390/microorganisms9091948] [Reference Citation Analysis]
228 Sbeit W, Khoury T, Kadah A, Asadi W, Shahin A, Lubany A, Safadi M, Haddad H, Abu Ahmad R, Abu El Hija S, Abboud R, Mahamid M, Pellicano R, Mari A. Proton Pump Inhibitor Use May Increase the Risk of Diverticulitis but Not It's Severity among Patients with Colonic Diverticulosis: A Multicenter Study. J Clin Med 2020;9:E2966. [PMID: 32937926 DOI: 10.3390/jcm9092966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
229 Yang L, Zhang J, Xu J, Wei X, Yang J, Liu Y, Li H, Zhao C, Wang Y, Zhang L, Gai Z. Helicobacter pylori Infection Aggravates Dysbiosis of Gut Microbiome in Children With Gastritis. Front Cell Infect Microbiol 2019;9:375. [PMID: 31781514 DOI: 10.3389/fcimb.2019.00375] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
230 Singh A, Garg R, Lan N, Siddiqui MT, Gupta M, Alkhouri N. Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:591-8. [DOI: 10.1007/s12664-020-01087-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer 2021;142:18-28. [PMID: 33212418 DOI: 10.1016/j.ejca.2020.09.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
232 Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, Spector TD, Bell JT, Clark AG, Ley RE. Genetic determinants of the gut microbiome in UK twins. Cell Host Microbe. 2016;19:731-743. [PMID: 27173935 DOI: 10.1016/j.chom.2016.04.017] [Cited by in Crossref: 502] [Cited by in F6Publishing: 411] [Article Influence: 100.4] [Reference Citation Analysis]
233 Weltermann T, Schulz C, Macke L. Effect of frequently prescribed drugs on gastric cancer risk. Best Pract Res Clin Gastroenterol 2021;50-51:101741. [PMID: 33975680 DOI: 10.1016/j.bpg.2021.101741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
234 Durán C, Ciucci S, Palladini A, Ijaz UZ, Zippo AG, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nat Commun 2021;12:1926. [PMID: 33771992 DOI: 10.1038/s41467-021-22135-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
235 Nadatani Y, Watanabe T, Suda W, Nakata A, Matsumoto Y, Kosaka S, Higashimori A, Otani K, Hosomi S, Tanaka F, Nagami Y, Kamata N, Taira K, Yamagami H, Tanigawa T, Hattori M, Fujiwara Y. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii. Sci Rep 2019;9:17490. [PMID: 31767915 DOI: 10.1038/s41598-019-53559-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
236 Chavira A, Belda-ferre P, Kosciolek T, Ali F, Dorrestein PC, Knight R. The Microbiome and Its Potential for Pharmacology. In: Barrett JE, Page CP, Michel MC, editors. Concepts and Principles of Pharmacology. Cham: Springer International Publishing; 2019. pp. 301-26. [DOI: 10.1007/164_2019_317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
237 He C, Peng C, Wang H, Ouyang Y, Zhu Z, Shu X, Zhu Y, Lu N. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter 2019. [DOI: 10.1111/hel.12590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
238 Maggi DC, Borgonovo A, Bansho ET, Soares-silva PE, Silva TE, Colombo BS, Wildner LM, Bazzo ML, Dantas-correa EB, Narciso-schiavon JL, Schiavon LL. Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis. Annals of Hepatology 2019;18:331-7. [DOI: 10.1016/j.aohep.2018.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
239 Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 2017; Epub ahead of print. [PMID: 29273641 DOI: 10.1136/gutjnl-2017-315710] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
240 Craig SJC, Blankenberg D, Parodi ACL, Paul IM, Birch LL, Savage JS, Marini ME, Stokes JL, Nekrutenko A, Reimherr M, Chiaromonte F, Makova KD. Child Weight Gain Trajectories Linked To Oral Microbiota Composition. Sci Rep 2018;8:14030. [PMID: 30232389 DOI: 10.1038/s41598-018-31866-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
241 Maruyama M, Goshi S, Kashima Y, Mizuhara A, Higashiguchi T. Clinical Effects of a Pectin-Containing Oligomeric Formula in Tube Feeding Patients: A Multicenter Randomized Clinical Trial. Nutr Clin Pract 2020;35:464-70. [PMID: 31606903 DOI: 10.1002/ncp.10392] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
242 Kawashima R, Tamaki S, Kawakami F, Maekawa T, Ichikawa T. Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis. Int J Mol Sci 2020;21:E8166. [PMID: 33142910 DOI: 10.3390/ijms21218166] [Reference Citation Analysis]
243 Chen LA, Hourigan SK, Grigoryan Z, Gao Z, Clemente JC, Rideout JR, Chirumamilla S, Rabidazeh S, Saeed S, Elson CO, Oliva-Hemker M, Blaser MJ, Sears CL. Decreased Fecal Bacterial Diversity and Altered Microbiome in Children Colonized With Clostridium difficile. J Pediatr Gastroenterol Nutr 2019;68:502-8. [PMID: 30540709 DOI: 10.1097/MPG.0000000000002210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
244 Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urol Nephrol 2021;73:462-70. [PMID: 33769018 DOI: 10.23736/S2724-6051.21.04116-3] [Reference Citation Analysis]
245 Lin YT, Lin TY, Hung SC, Liu PY, Wu PH, Chuang YS, Hung WC, Chiu YW, Kuo MC, Wu CY. Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients. Microorganisms 2021;9:286. [PMID: 33573326 DOI: 10.3390/microorganisms9020286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Madison AA, Kiecolt-Glaser JK. The gut microbiota and nervous system: Age-defined and age-defying. Semin Cell Dev Biol 2021;116:98-107. [PMID: 33422403 DOI: 10.1016/j.semcdb.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Kohi S, Macgregor-Das A, Dbouk M, Yoshida T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31519-6. [PMID: 33161160 DOI: 10.1016/j.cgh.2020.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
248 Murata M, Sugimoto M, Otsuka T, Nishida A, Inatomi O, Bamba S, Andoh A. Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation. Helicobacter 2018;23. [DOI: 10.1111/hel.12543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
249 Kikuchi R, Irie J, Yamada-Goto N, Kikkawa E, Seki Y, Kasama K, Itoh H. The Impact of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Intestinal Microbiota Differs from that of Laparoscopic Sleeve Gastrectomy in Japanese Patients with Obesity.Clin Drug Investig. 2018;38:545-552. [PMID: 29508311 DOI: 10.1007/s40261-018-0638-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
250 Biver E, Berenbaum F, Valdes AM, Araujo de Carvalho I, Bindels LB, Brandi ML, Calder PC, Castronovo V, Cavalier E, Cherubini A, Cooper C, Dennison E, Franceschi C, Fuggle N, Laslop A, Miossec P, Thomas T, Tuzun S, Veronese N, Vlaskovska M, Reginster JY, Rizzoli R. Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Res Rev. 2019;55:100946. [PMID: 31437484 DOI: 10.1016/j.arr.2019.100946] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
251 Kuan YC, Huang KW, Lin CL, Luo JC, Kao CH. Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis. J Clin Med 2019;8:E1108. [PMID: 31349746 DOI: 10.3390/jcm8081108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
252 Søgaard M, Heide-Jørgensen U, Vandenbroucke JP, Schønheyder HC, Vandenbroucke-Grauls CMJE. Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study. Clin Microbiol Infect 2017;23:952-60. [PMID: 28377310 DOI: 10.1016/j.cmi.2017.03.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
253 Vandenplas Y, Hauser B, Salvatore S. Functional Gastrointestinal Disorders in Infancy: Impact on the Health of the Infant and Family. Pediatr Gastroenterol Hepatol Nutr 2019;22:207-16. [PMID: 31110953 DOI: 10.5223/pghn.2019.22.3.207] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
254 Lee SM, Kim N, Nam RH, Park JH, Choi SI, Park YT, Kim YR, Seok YJ, Shin CM, Lee DH. Gut microbiota and butyrate level changes associated with the long-term administration of proton pump inhibitors to old rats. Sci Rep 2019;9:6626. [PMID: 31036935 DOI: 10.1038/s41598-019-43112-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
255 Choi DS, Seo SI, Shin WG, Park CH. Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis. Clin Transl Gastroenterol 2020;11:e00127. [PMID: 32032128 DOI: 10.14309/ctg.0000000000000127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
256 Wroblewski LE, Peek RM Jr, Coburn LA. The Role of the Microbiome in Gastrointestinal Cancer. Gastroenterol Clin North Am 2016;45:543-56. [PMID: 27546848 DOI: 10.1016/j.gtc.2016.04.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
257 Kawar N, Park SG, Schwartz JL, Callahan N, Obrez A, Yang B, Chen Z, Adami GR. Salivary microbiome with gastroesophageal reflux disease and treatment. Sci Rep 2021;11:188. [PMID: 33420219 DOI: 10.1038/s41598-020-80170-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Fossmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. Int J Mol Sci 2019;20:E5203. [PMID: 31640115 DOI: 10.3390/ijms20205203] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
259 Nycz J, Zajdel A. Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii. Postępy Higieny i Medycyny Doświadczalnej 2021;75:762-72. [DOI: 10.2478/ahem-2021-0009] [Reference Citation Analysis]
260 Zhou Y, Ye Z, Wang Y, Huang Z, Zheng C, Shi J, Tang W, Zhang P, Wang S, Huang Y. Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children. Helicobacter 2021;26:e12809. [PMID: 33899288 DOI: 10.1111/hel.12809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Menni C, Zierer J, Pallister T, Jackson MA, Long T, Mohney RP, Steves CJ, Spector TD, Valdes AM. Omega-3 fatty acids correlate with gut microbiome diversity and production of N-carbamylglutamate in middle aged and elderly women. Sci Rep 2017;7:11079. [PMID: 28894110 DOI: 10.1038/s41598-017-10382-2] [Cited by in Crossref: 100] [Cited by in F6Publishing: 83] [Article Influence: 20.0] [Reference Citation Analysis]
262 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
263 Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2018;. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
264 D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J 2021;9:451-60. [PMID: 33961734 DOI: 10.1002/ueg2.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
265 Ibáñez-Sanz G, Milà N, de la Peña-Negro LC, Garcia M, Vidal C, Rodríguez-Alonso L, Binefa G, Rodríguez-Moranta F, Moreno V. Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing. J Gastroenterol 2021;56:42-53. [PMID: 33159805 DOI: 10.1007/s00535-020-01738-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
266 Quigley EM. Basic Definitions and Concepts: Organization of the Gut Microbiome. Gastroenterol Clin North Am 2017;46:1-8. [PMID: 28164844 DOI: 10.1016/j.gtc.2016.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
267 Lepczyńska M, Dzika E, Chen W, Lu CY. Influence of Proton Pump Inhibitors and Histamine Receptor 2 Antagonists on Blastocystis ST3 and Selected Microorganisms of Intestinal Microbiota In Vitro. Clin Transl Gastroenterol 2021;12:e00325. [PMID: 33835078 DOI: 10.14309/ctg.0000000000000325] [Reference Citation Analysis]
268 Chamniansawat S, Kampuang N, Suksridechacin N, Thongon N. Ultrastructural intestinal mucosa change after prolonged inhibition of gastric acid secretion by omeprazole in male rats. Anat Sci Int 2021;96:142-56. [PMID: 32931001 DOI: 10.1007/s12565-020-00572-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Wu L, Wang Z, Sun G, Peng L, Lu Z, Yan B, Huang K, Yang Y. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep 2019;9:12874. [PMID: 31492912 DOI: 10.1038/s41598-019-49415-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
270 Chawla BK, Cohen RE, Yerke LM. Association between proton pump inhibitors and periodontal disease severity. Clin Exp Dent Res 2021. [PMID: 34545705 DOI: 10.1002/cre2.495] [Reference Citation Analysis]
271 Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.Int J Mol Sci. 2020;21. [PMID: 32046317 DOI: 10.3390/ijms21031136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
272 Nayak RR, Turnbaugh PJ. Mirror, mirror on the wall: which microbiomes will help heal them all? BMC Med. 2016;14:72. [PMID: 27146150 DOI: 10.1186/s12916-016-0622-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
273 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
274 Dharmaratne P, Rahman N, Leung A, Ip M. Is there a role of faecal microbiota transplantation in reducing antibiotic resistance burden in gut? A systematic review and Meta-analysis. Ann Med 2021;53:662-81. [PMID: 34170204 DOI: 10.1080/07853890.2021.1927170] [Reference Citation Analysis]
275 Ding JH, Jin Z, Yang XX, Lou J, Shan WX, Hu YX, Du Q, Liao QS, Xie R, Xu JY. Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World J Gastroenterol 2020; 26(40): 6141-6162 [PMID: 33177790 DOI: 10.3748/wjg.v26.i40.6141] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
276 Liu S. The Development of Our Organ of Other Kinds-The Gut Microbiota. Front Microbiol 2016;7:2107. [PMID: 28066404 DOI: 10.3389/fmicb.2016.02107] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
277 Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Target Oncol 2021. [PMID: 34894318 DOI: 10.1007/s11523-021-00861-y] [Reference Citation Analysis]
278 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 300] [Article Influence: 100.3] [Reference Citation Analysis]
279 Le Bastard Q, Al-Ghalith GA, Grégoire M, Chapelet G, Javaudin F, Dailly E, Batard E, Knights D, Montassier E. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther 2018;47:332-45. [PMID: 29205415 DOI: 10.1111/apt.14451] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 18.8] [Reference Citation Analysis]
280 Read E, Curtis MA, Neves JF. The role of oral bacteria in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:731-42. [PMID: 34400822 DOI: 10.1038/s41575-021-00488-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Wehkamp J, Frick JS. Microbiome and chronic inflammatory bowel diseases. J Mol Med (Berl) 2017;95:21-8. [PMID: 27988792 DOI: 10.1007/s00109-016-1495-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
282 Menni C. Lessons on dietary biomarkers from twin studies. Proc Nutr Soc 2017;76:303-7. [PMID: 28134072 DOI: 10.1017/S0029665116002810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
283 Clos-Garcia M, Andrés-Marin N, Fernández-Eulate G, Abecia L, Lavín JL, van Liempd S, Cabrera D, Royo F, Valero A, Errazquin N, Vega MCG, Govillard L, Tackett MR, Tejada G, Gónzalez E, Anguita J, Bujanda L, Orcasitas AMC, Aransay AM, Maíz O, López de Munain A, Falcón-Pérez JM. Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia.EBioMedicine. 2019;46:499-511. [PMID: 31327695 DOI: 10.1016/j.ebiom.2019.07.031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
284 Yasutomi E, Hoshi N, Adachi S, Otsuka T, Kong L, Ku Y, Yamairi H, Inoue J, Ishida T, Watanabe D, Ooi M, Yoshida M, Tsukimi T, Fukuda S, Azuma T. Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria. Dig Dis Sci 2018;63:881-9. [DOI: 10.1007/s10620-017-4905-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
285 Bilello J, Okereke I. Impact of Environmental and Pharmacologic Changes on the Upper Gastrointestinal Microbiome. Biomedicines 2021;9:617. [PMID: 34072493 DOI: 10.3390/biomedicines9060617] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Mahon J, Lifschitz C, Ludwig T, Thapar N, Glanville J, Miqdady M, Saps M, Quak SH, Lenoir Wijnkoop I, Edwards M, Wood H, Szajewska H. The costs of functional gastrointestinal disorders and related signs and symptoms in infants: a systematic literature review and cost calculation for England. BMJ Open 2017;7:e015594. [PMID: 29138194 DOI: 10.1136/bmjopen-2016-015594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
287 Horvath A, Bausys A, Sabaliauskaite R, Stratilatovas E, Jarmalaite S, Schuetz B, Stiegler P, Bausys R, Stadlbauer V, Strupas K. Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study. Ann Surg Oncol. 2021;28:1198-1208. [PMID: 32504369 DOI: 10.1245/s10434-020-08678-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
288 Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, Tsuchiya S, Okayama T, Dohi O, Yoshida N, Kamada K, Ishikawa T, Handa O, Konishi H, Okuda K, Tsujimoto Y, Ohnogi H, Itoh Y. The influence of long-term use of proton pump inhibitors on the gut microbiota: An age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62:100-105. [PMID: 29371761 DOI: 10.3164/jcbn.17-78] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 10.6] [Reference Citation Analysis]
289 Menni C, Lin C, Cecelja M, Mangino M, Matey-Hernandez ML, Keehn L, Mohney RP, Steves CJ, Spector TD, Kuo CF, Chowienczyk P, Valdes AM. Gut microbial diversity is associated with lower arterial stiffness in women. Eur Heart J 2018;39:2390-7. [PMID: 29750272 DOI: 10.1093/eurheartj/ehy226] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 31.7] [Reference Citation Analysis]
290 Omori K, Miyakawa H, Watanabe A, Nakayama Y, Lyu Y, Ichikawa N, Sasaki H, Shibata S. The Combined Effects of Magnesium Oxide and Inulin on Intestinal Microbiota and Cecal Short-Chain Fatty Acids. Nutrients 2021;13:E152. [PMID: 33466274 DOI: 10.3390/nu13010152] [Reference Citation Analysis]
291 Kamo T, Akazawa H, Suda W, Saga-Kamo A, Shimizu Y, Yagi H, Liu Q, Nomura S, Naito AT, Takeda N, Harada M, Toko H, Kumagai H, Ikeda Y, Takimoto E, Suzuki JI, Honda K, Morita H, Hattori M, Komuro I. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One 2017;12:e0174099. [PMID: 28328981 DOI: 10.1371/journal.pone.0174099] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 17.8] [Reference Citation Analysis]
292 Hansen TH, Thomassen MT, Madsen ML, Kern T, Bak EG, Kashani A, Allin KH, Hansen T, Pedersen O. The effect of drinking water pH on the human gut microbiota and glucose regulation: results of a randomized controlled cross-over intervention. Sci Rep 2018;8:16626. [PMID: 30413727 DOI: 10.1038/s41598-018-34761-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
293 Mougey EB, Nguyen V, Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Borrell B, Román E, González-Lois C, Chao M, Al-Atrash H, Franciosi JP. STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-term Proton Pump Inhibitor Therapy. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31129-0. [PMID: 32798708 DOI: 10.1016/j.cgh.2020.08.020] [Reference Citation Analysis]
294 Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:246-58. [PMID: 29105111 DOI: 10.1111/apt.14391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
295 Zheng YM, Chen XY, Cai JY, Yuan Y, Xie WR, Xu JT, Xia HHX, Zhang M, He XX, Wu LH. Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease. World J Gastroenterol 2021; 27(6): 513-522 [PMID: 33642825 DOI: 10.3748/wjg.v27.i6.513] [Reference Citation Analysis]
296 Ciucci S, Ge Y, Durán C, Palladini A, Jiménez-Jiménez V, Martínez-Sánchez LM, Wang Y, Sales S, Shevchenko A, Poser SW, Herbig M, Otto O, Androutsellis-Theotokis A, Guck J, Gerl MJ, Cannistraci CV. Enlightening discriminative network functional modules behind Principal Component Analysis separation in differential-omic science studies. Sci Rep 2017;7:43946. [PMID: 28287094 DOI: 10.1038/srep43946] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
297 Kwon SK, Park JC, Kim KH, Yoon J, Cho Y, Lee B, Lee JJ, Jeong H, Oh Y, Kim SH, Lee SD, Hwang BR, Chung Y, Kim JF, Nam KT, Lee YC. Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice. Gut 2021:gutjnl-2021-324489. [PMID: 34389621 DOI: 10.1136/gutjnl-2021-324489] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
298 Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH, Quesenberry CP, Corley DA. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol 2020;115:706-15. [DOI: 10.14309/ajg.0000000000000591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
299 Lagier J. Gut microbiota and Clostridium difficile infections. Human Microbiome Journal 2016;2:10-4. [DOI: 10.1016/j.humic.2016.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
300 Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67:1716-1725. [PMID: 29934437 DOI: 10.1136/gutjnl-2018-316723] [Cited by in Crossref: 447] [Cited by in F6Publishing: 405] [Article Influence: 111.8] [Reference Citation Analysis]
301 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int. 2020;14:24-34. [PMID: 31797303 DOI: 10.1007/s12072-019-10004-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
302 Motta BM, Grander C, Gögele M, Foco L, Vukovic V, Melotti R, Fuchsberger C, De Grandi A, Cantaloni C, Picard A, Mascalzoni D, Rossini A, Pattaro C, Tilg H, Pramstaller PP. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. J Transl Med 2019;17:408. [PMID: 31801616 DOI: 10.1186/s12967-019-02130-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
303 Taha AS. Vonoprazan, aspirin and NSAIDs: new era in acid inhibition and gastroprotection. Gut 2018;67:995-6. [PMID: 29208676 DOI: 10.1136/gutjnl-2017-315252] [Reference Citation Analysis]
304 Tanaka T, Matsuno Y, Torisu T, Shibata H, Hirano A, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Moriyama T, Esaki M, Kitazono T. Gastric microbiota in patients with Helicobacter pylori-negative gastric MALT lymphoma. Medicine (Baltimore) 2021;100:e27287. [PMID: 34559138 DOI: 10.1097/MD.0000000000027287] [Reference Citation Analysis]
305 Zheng P, Li Z, Zhou Z. Gut microbiome in type 1 diabetes: A comprehensive review. Diabetes Metab Res Rev 2018;34:e3043. [PMID: 29929213 DOI: 10.1002/dmrr.3043] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 13.8] [Reference Citation Analysis]
306 Ticinesi A, Milani C, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA, Turroni F, Duranti S, Mangifesta M, Viappiani A, Ferrario C, Maggio M, Ventura M, Meschi T. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep 2017;7:11102. [PMID: 28894183 DOI: 10.1038/s41598-017-10734-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 16.6] [Reference Citation Analysis]
307 Hakozaki T, Okuma Y, Omori M, Hosomi Y. Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett 2019;17:2946-52. [PMID: 30854072 DOI: 10.3892/ol.2019.9899] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
308 Kaur G, Behl T, Bungau S, Kumar A, Uddin MS, Mehta V, Zengin G, Mathew B, Shah MA, Arora S. Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson's Disease. Curr Neuropharmacol 2021;19:233-47. [PMID: 32504503 DOI: 10.2174/1570159X18666200606233050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
309 Giannone G, Ghisoni E, Genta S, Scotto G, Tuninetti V, Turinetto M, Valabrega G. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. Int J Mol Sci 2020;21:E4414. [PMID: 32575899 DOI: 10.3390/ijms21124414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
310 Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, Heidrich B. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scand J Gastroenterol 2019;54:1033-41. [PMID: 31361979 DOI: 10.1080/00365521.2019.1647280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
311 Rowin J. Integrative neuromuscular medicine: Neuropathy and neuropathic pain: Consider the alternatives. Muscle Nerve 2019;60:124-36. [DOI: 10.1002/mus.26510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
312 Zheng YF, Liang SP, Zhong ZS, Zhang W, Wu YY, Liu JB, Huang SP. Duodenal microbiota makes an important impact in functional dyspepsia. Microb Pathog 2021;162:105297. [PMID: 34883227 DOI: 10.1016/j.micpath.2021.105297] [Reference Citation Analysis]
313 Mishiro T, Oka K, Kuroki Y, Takahashi M, Tatsumi K, Saitoh T, Tobita H, Ishimura N, Sato S, Ishihara S, Sekine J, Wada K, Kinoshita Y. Oral microbiome alterations of healthy volunteers with proton pump inhibitor. J Gastroenterol Hepatol. 2018;33:1059-1066. [PMID: 29105152 DOI: 10.1111/jgh.14040] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
314 Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gillilland MG 3rd, Hayashi A, Imai J, Sugihara K, Miyoshi M, Brazil JC, Kuffa P, Hill BD, Rizvi SM, Wen F, Bishu S, Inohara N, Eaton KA, Nusrat A, Lei YL, Giannobile WV, Kamada N. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell 2020;182:447-462.e14. [PMID: 32758418 DOI: 10.1016/j.cell.2020.05.048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 29.5] [Reference Citation Analysis]
315 Hakuta R, Nakai Y, Hamada T, Nomura Y, Saito T, Takahara N, Mizuno S, Kogure H, Moriya K, Koike K. Use of proton pump inhibitors and cholangitis complicated with multi-drug resistant bacteria. J Hepatobiliary Pancreat Sci 2021. [PMID: 34382333 DOI: 10.1002/jhbp.1035] [Reference Citation Analysis]
316 Walker MM, Talley NJ. The Role of Duodenal Inflammation in Functional Dyspepsia. Journal of Clinical Gastroenterology 2017;51:12-8. [DOI: 10.1097/mcg.0000000000000740] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
317 Labenz J. [Conservative Therapy of Reflux Disease and its Limits]. Zentralbl Chir 2021;146:176-87. [PMID: 33598907 DOI: 10.1055/a-1309-2368] [Reference Citation Analysis]
318 Brusselaers N. Prescribed Drugs and the Microbiome. Gastroenterol Clin North Am 2019;48:331-42. [PMID: 31383274 DOI: 10.1016/j.gtc.2019.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
319 Adolph TE, Grander C, Moschen AR, Tilg H. Liver–Microbiome Axis in Health and Disease. Trends in Immunology 2018;39:712-23. [DOI: 10.1016/j.it.2018.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
320 Chen Z, Maqbool J, Sajid F, Hussain G, Sun T. Human gut microbiota and its association with pathogenesis and treatments of neurodegenerative diseases. Microb Pathog 2021;150:104675. [PMID: 33352217 DOI: 10.1016/j.micpath.2020.104675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Gutiérrez-Repiso C, Moreno-Indias I, Martín-Núñez GM, Ho-Plagaro A, Ocaña-Wilhelmi L, Fernández García D, Gonzalo Marín M, Moreno-Ruiz FJ, García-Fuentes E, Tinahones FJ. Influence of Factors Altering Gastric Microbiota on Bariatric Surgery Metabolic Outcomes. Microbiol Spectr 2021;:e0053521. [PMID: 34787463 DOI: 10.1128/Spectrum.00535-21] [Reference Citation Analysis]
322 Martinsen TC, Fossmark R, Waldum HL. The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid. Int J Mol Sci 2019;20:E6031. [PMID: 31795477 DOI: 10.3390/ijms20236031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
323 Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A. Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2018;12:899-906. [PMID: 30040500 DOI: 10.1080/17474124.2018.1503946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
324 Kostrzewska M, Świdnicka-Siergiejko A, Olszańska D, Jurkowska G, Garley M, Ratajczak-Wrona W, Jabłońska E, Jamiołkowski J, Dabrowski A. The effect of omeprazole treatment on the gut microflora and neutrophil function. Clin Res Hepatol Gastroenterol 2017;41:575-84. [PMID: 28258834 DOI: 10.1016/j.clinre.2017.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
325 McCormack R, Olley L, Glanemann B, Swann JW. Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care. Sci Rep 2020;10:15727. [PMID: 32978503 DOI: 10.1038/s41598-020-72950-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol 2019;20:e77-91. [PMID: 30712808 DOI: 10.1016/S1470-2045(18)30952-5] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 54.0] [Reference Citation Analysis]
327 Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol 2021;45:101397. [PMID: 32224118 DOI: 10.1016/j.clinre.2020.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
328 Hong S, Lee E, Shin J. Proton‐pump inhibitors and the risk of Clostridium difficile –associated diarrhea in high‐risk antibiotics users: A population‐based case‐crossover study. Pharmacoepidemiol Drug Saf 2019;28:479-88. [DOI: 10.1002/pds.4745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 Horvath A, Leber B, Feldbacher N, Steinwender M, Komarova I, Rainer F, Blesl A, Stadlbauer V. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Sci Rep 2020;10:2723. [PMID: 32066847 DOI: 10.1038/s41598-020-59550-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
330 Li Y, Yang S, Guo X, Chen Y. Prophylactic Use of Mucosal Protective Agents and Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Real World Evidences of 36,870 Patients. Journal of Cardiovascular Pharmacology 2019;74:137-42. [DOI: 10.1097/fjc.0000000000000684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
331 Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. ESMO Open 2021;6:100090. [PMID: 33740735 DOI: 10.1016/j.esmoop.2021.100090] [Reference Citation Analysis]
332 Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG; imCORE working group of early career investigators. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol 2020;31:525-31. [PMID: 32115349 DOI: 10.1016/j.annonc.2020.01.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 28.5] [Reference Citation Analysis]
333 Liu J, Lahousse L, Nivard MG, Bot M, Chen L, van Klinken JB, Thesing CS, Beekman M, van den Akker EB, Slieker RC, Waterham E, van der Kallen CJH, de Boer I, Li-Gao R, Vojinovic D, Amin N, Radjabzadeh D, Kraaij R, Alferink LJM, Murad SD, Uitterlinden AG, Willemsen G, Pool R, Milaneschi Y, van Heemst D, Suchiman HED, Rutters F, Elders PJM, Beulens JWJ, van der Heijden AAWA, van Greevenbroek MMJ, Arts ICW, Onderwater GLJ, van den Maagdenberg AMJM, Mook-Kanamori DO, Hankemeier T, Terwindt GM, Stehouwer CDA, Geleijnse JM, 't Hart LM, Slagboom PE, van Dijk KW, Zhernakova A, Fu J, Penninx BWJH, Boomsma DI, Demirkan A, Stricker BHC, van Duijn CM. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med 2020;26:110-7. [PMID: 31932804 DOI: 10.1038/s41591-019-0722-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
334 Sun J, Yin T, Zhou J, Xu J, Lu X. Gut microbiome and cancer immunotherapy. J Cell Physiol 2020;235:4082-8. [DOI: 10.1002/jcp.29359] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
335 Davies N, O’sullivan JM, Plank LD, Murphy R. Gut Microbial Predictors of Type 2 Diabetes Remission Following Bariatric Surgery. OBES SURG 2020;30:3536-48. [DOI: 10.1007/s11695-020-04684-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
336 Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut 2020;69:1510-9. [PMID: 32409589 DOI: 10.1136/gutjnl-2019-320204] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 22.5] [Reference Citation Analysis]
337 Frost F, Kacprowski T, Rühlemann M, Bang C, Franke A, Zimmermann K, Nauck M, Völker U, Völzke H, Biffar R, Schulz C, Mayerle J, Weiss FU, Homuth G, Lerch MM. Helicobacter pylori infection associates with fecal microbiota composition and diversity.Sci Rep. 2019;9:20100. [PMID: 31882864 DOI: 10.1038/s41598-019-56631-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
338 Tai CH, Hsu CN, Yang SC, Wu CK, Liang CM, Tai WC, Chuah SK, Lee CH. The impact of aspirin on Klebsiella pneumoniae liver abscess in diabetic patients. Sci Rep 2020;10:21329. [PMID: 33288865 DOI: 10.1038/s41598-020-78442-8] [Reference Citation Analysis]
339 Das B, Nair GB. Homeostasis and dysbiosis of the gut microbiome in health and disease. J Biosci 2019;44. [DOI: 10.1007/s12038-019-9926-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
340 Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin JY, Personeni N, Pressiani T, Nishida N, Lee PC, Lee CJ, Hildebrand H, Nimkar N, Paul S, Fessas P, Naeem M, Bettinger D, Khan U, Saeed A, Huang YH, Kudo M, Rimassa L, Marron TU, Pinato DJ, Ang C. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 2021;13:17588359211010937. [PMID: 33995594 DOI: 10.1177/17588359211010937] [Reference Citation Analysis]
341 Li C, Xia Z, Li A, Meng J. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ann Transl Med 2020;8:1655. [PMID: 33490167 DOI: 10.21037/atm-20-7498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
342 Segregur D, Flanagan T, Mann J, Moir A, Karlsson EM, Hoch M, Carlile D, Sayah-jeanne S, Dressman J. Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes. Journal of Pharmaceutical Sciences 2019;108:3461-77. [DOI: 10.1016/j.xphs.2019.06.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
343 Hagi T, Belzer C. The interaction of Akkermansia muciniphila with host-derived substances, bacteria and diets. Appl Microbiol Biotechnol 2021;105:4833-41. [PMID: 34125276 DOI: 10.1007/s00253-021-11362-3] [Reference Citation Analysis]
344 Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, Kuipers F, Wijmenga C, Fu J. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 2018;9:432-45. [PMID: 29705929 DOI: 10.1007/s13238-018-0547-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
345 Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. Hepatol Res 2020;50:407-18. [PMID: 31840358 DOI: 10.1111/hepr.13473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
346 Menni C, Jackson MA, Pallister T, Steves CJ, Spector TD, Valdes AM. Gut microbiome diversity and high-fibre intake are related to lower long-term weight gain. Int J Obes (Lond) 2017;41:1099-105. [PMID: 28286339 DOI: 10.1038/ijo.2017.66] [Cited by in Crossref: 145] [Cited by in F6Publishing: 125] [Article Influence: 29.0] [Reference Citation Analysis]
347 Tantai XX, Yang LB, Wei ZC, Xiao CL, Chen LR, Wang JH, Liu N. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683-2698 [PMID: 31210719 DOI: 10.3748/wjg.v25.i21.2683] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
348 Wu S, Jiang P, Zhao XM, Chen WH. Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis. Cell Metab 2021;33:455-6. [PMID: 33657385 DOI: 10.1016/j.cmet.2021.02.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
349 Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. Digestion. 2018;97:195-204. [PMID: 29316555 DOI: 10.1159/000481813] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 11.0] [Reference Citation Analysis]
350 Debelius J, Song SJ, Vazquez-Baeza Y, Xu ZZ, Gonzalez A, Knight R. Tiny microbes, enormous impacts: what matters in gut microbiome studies? Genome Biol 2016;17:217. [PMID: 27760558 DOI: 10.1186/s13059-016-1086-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
351 Abdel-Aziz MI, Vijverberg SJH, Neerincx AH, Kraneveld AD, Maitland-van der Zee AH. The crosstalk between microbiome and asthma: Exploring associations and challenges. Clin Exp Allergy 2019;49:1067-86. [PMID: 31148278 DOI: 10.1111/cea.13444] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
352 Roland BC, Lee D, Miller LS, Vegesna A, Yolken R, Severance E, Prandovszky E, Zheng XE, Mullin GE. Obesity increases the risk of small intestinal bacterial overgrowth (SIBO). Neurogastroenterol Motil 2018;30:e13199. [DOI: 10.1111/nmo.13199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
353 Sánchez-Trigueros MI, Méndez-Cruz F, Pineda-Peña EA, Rivera-Espinoza Y, Castañeda-Hernández G, Chávez-Piña AE. Synergistic protective effects between docosahexaenoic acid and omeprazole on the gastrointestinal tract in the indomethacin-induced injury model. Drug Dev Res 2021;82:543-52. [PMID: 33319390 DOI: 10.1002/ddr.21772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
354 Stark CM, Susi A, Emerick J, Nylund CM. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut. 2019;68:62-69. [PMID: 30377188 DOI: 10.1136/gutjnl-2017-314971] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
355 Maier L, Typas A. Systematically investigating the impact of medication on the gut microbiome. Curr Opin Microbiol 2017;39:128-35. [PMID: 29169088 DOI: 10.1016/j.mib.2017.11.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
356 Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M, Albera C, Antoniou KM, Altinisik G, Bendstrup E, Bondue B, Borie R, Brown KK, Camus P, Castillo D, Collard HR, Cottin V, Crimi N, Ferrara G, Fischer A, Gauldie J, Geiser T, Guenther A, Hambly N, Hansell DM, Harari S, Jones MG, Keane M, Ley B, Maher TM, Molina-molina M, Palmucci S, Poletti V, Prasse A, Rottoli P, Spagnolo P, Sterclova M, Torrisi S, Tsitoura E, Vasakova M, Walsh SL, Wijsenbeek MS, Wuyts WA. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? The Lancet Respiratory Medicine 2017;5:591-8. [DOI: 10.1016/s2213-2600(17)30219-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 8.8] [Reference Citation Analysis]
357 Vijay A, Astbury S, Le Roy C, Spector TD, Valdes AM. The prebiotic effects of omega-3 fatty acid supplementation: A six-week randomised intervention trial. Gut Microbes 2021;13:1-11. [PMID: 33382352 DOI: 10.1080/19490976.2020.1863133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]